Report Store Get Proposal

Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Home Blog Immunological and autoimmune disorders 5

Immunological and Autoimmune Disorders

Pharma News for Pfizer, Daiichi Sankyo, Kyverna, Servier

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO

FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer Inc. announced that the FDA has authorized ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in people aged 60 and up. ABRYSVO is an unadjuvanted vaccine made up of two preF proteins chosen to maximize protection against RSV A and B strains, and it has been shown to be both safe and efficacious. "For over a half-century, a vaccine to help prevent RSV had been an elusive public health goal." "Today's approval is a sig...

Explore More...

Pharma News and Updates for AstraZeneca, Supernus, and BMS

VBL Therapeutics’ VB-111 (ofranergene obadenovec); BMS’s mavacamten (Camzyos); Merck’s KEYTRUDA; AstraZeneca and Daiichi’s Enhertu; Pfizer/Biohaven’s VYDURA (rimegepant); AstraZeneca’s Ultomiris; Supernus’s Viloxazine (Qlebree); AbbVie’s Rinvoq

Ankylosing Spondylitis Treatment Market Analysis

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Pharma News and Updates for Sanofi ViiV Argenx Novartis UCB Kyowa

Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Potential of Cannabidiol (CBD) as a Treatment Substance

Can Cannabinoids be an Effective Medicinal Substance?

MedTech News and Updates for LivaNova, Medtronic, Conformis, Noninvasix, Masimo

Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study

pharma-news-for-gsk-idorsia-bms-novartis-lilly-cantex-viatris-biocon

GSK’s Covifenz; Idorsia’s Quviviq; GSK’s ZEJULA; EMA Expands its Nod for BMS, Eli Lilly, and Novartis Drugs; Cantex Secures Global Licence to Develop Azeliragon; Biocon Acquires Viatris’ Biosimilar Business

pharma-news-for-pfizer-lilly-innovent-bayer-gsk-daewon

Pfizer & Lilly’s JAK Inhibitors Drug; FDA Approves Lilly’s Bebtelovimab; GSK’s Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian

major-pharmaceutical-companies-by-continents

Mapping the Biggest Pharmaceutical Companies by Continents

pharma-news-immunocore-samsung-novavax-merck-roche-gbt

Immunocore’s Kimmtrak; Samsung Acquires Biogen’s Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor

upcoming-drugs-for-autoimmune-diseases

Evaluating the Upcoming Drugs in Pipeline for Major Autoimmune Diseases

pharma-news-for-merck-pfizer-gilead-abbvie-lantern-polpharma

Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent

medtech-news-for-siemens-paragon-28-pulnovo-endotronix-abbott

Siemens Healthineers’s COVID-19 Antigen Self-Test; Paragon’s R3ACT Stabilization System; Pulnovo Medical’s PADN-CFDA trial; Endotronix’s PROACTIVE-HF trial; Abbott’s Proclaim XR SCS System; RTI Surgical spins off businesses

drugs-launched-in-second-half-2021

Assessment of Key Products that Got FDA Approval in Second Half (H2) of 2021

pharma-news-for-accutar-bio-thera-nykode-heat-biologics-elusys

Accutar’s Phase I clinical trial for AC0176; Bio-Thera’s cancer drug, BAT6005; Nykode’s Covid-19 vaccine trial; Heat Biologics acquires Elusys

monoclonal-antibody-therapy

What are Monoclonal Antibodies and How Can They Treat COVID-19?

progressive-parkinsons-disease-market

Evaluation of Rapidly Evolving Parkinson’s Disease Therapeutic Market

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly